Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.
⁃ • Meeting all the following criteria:
• Aged 40 and above; less than 75 years.
• Hypertensive patients currently taking at least one antihypertensive medication as recommended by guidelines, and blood pressure is within the target range (\<140/90 mmHg).
• The left atrial volume index measured by transthoracic echocardiography exceeds 34 mL/m², or the ratio of the average E/e' \>9 and left atrial volume index \>= 29 mL/m² measured by transthoracic echocardiography.
• Signing an informed consent form.